Search PubMed⌕ Search

Biomedical subjects

M Izuo

Publications and source records attributed to M Izuo.

At least 73 records · Page 4Linked to original sources
PubMed1988

[A clinico-pathological study regarding the incidence of intranuclear cytoplasmic inclusions (ICI) in cases of papillary thyroid carcinoma].

Intranuclear cytoplasmic inclusions (ICI) in 38 cases of thyroid papillary carcinomas have been studied as to the relationship between the frequency of ICI and the clinical, histological, and cytological findings of the carcinoma. ICI were present in all cases. The frequency of ICI in the cases studied ranged from +/- (one per several fields) to ¿ (more than ten per one field), using a microscope of 400 magnifications, and from 1.3% to 11.6% (mean value: 3.9%) of the nuclei of the carcinomas. The frequency of ICI was found to be influenced by the state of the nuclear chromatin and pleomorphism, but was not influenced by the papillary or follicular tumor growth. The relationship between the frequency of ICI and the tumor size and the existence of lymph-nodes metastasis, however, was not clarified.

Adolescent↗
PubMed1988

[Two cases of a lipid-secreting carcinoma of the breast].

Two very rare cases of a lipid-secreting carcinoma of the breast are reported, and a review of the pertinent literature. The patients were both women, aged 70 and 81, respectively. Both of their clinical stagings were T2aN1aM0, stage II., and radical mastectomies were performed. On examination of the resected specimens, the tumors did not differ from the general findings of breast cancer. Microscopically, H-E stain showed the tumor cells to have a foamy and vacuolated eosinophilic cytoplasm. Lipid stain and an electron microscopic study were performed and showed that the tumor cells contained large amounts of neutral lipid droplets in their cytoplasm.

Aged↗
PubMed1988

[Local forms of the treatment of recurrent breast cancer].

Recurrent breast cancer was classified into the following three groups; I: local skin (chest wall) recurrence including regional lymph nodes (61 cases), II: distant metastasis (93 cases), and III: local plus distant metastasis (33 cases). In this study, the results and evaluation of local forms of treatment for these recurrent breast cancers were analysed. Radiation therapy and surgical resection were mainly used for 61 patients with local recurrence at the primary site (32 skin, 24 lymph node and 5 skin plus lymph node). In most cases, however, various systemic treatments were combined or given consecutively. Response rate to radiation was high. The five-year survival rate after therapy for recurrence was 17% for radiation, 24% for resection with or without combination therapy and 14% for combined or other treatments. Surgical resection produced more long-term surviving patients. The solitary large nodule type of skin recurrence showed better prognosis than multiple small nodules or the diffusely infiltrating type. Recently, wide excision of the anterior breast wall with reconstruction has been performed and this contributes to improving the quality of life and survival. In addition, it is important that local treatment for recurrent breast cancer should be conducted along with a multidisciplinary approach using systemic combination therapy.

Adult↗
PubMed1988

[Clinical evaluation of adriamycin in advanced and recurrent breast cancer (No. 4)--Joint study by 30 institutes on the duration of remission using various maintenance therapies in patients treated with CAF. Clinical Study Group of Adriamycin for Breast Cancer in Japan].

In order to further extend the duration of remission induced by high-dose CAF therapy, maintenance therapies based on long-term oral administration of cyclophosphamide and fluorouracil (CF) were applied for patients with advanced and recurrent breast cancer. The duration of remission was compared by the envelope method among the basic therapy (Arm I), Arm I plus intermittent administration of adriamycin (Arm II) and Arm I plus tamoxifen from the start of high-dose CAF therapy (Arm III). The response rate of 163 evaluable patients in 30 institutes was 42.1% (27/57) and 44.4% (25/54) for Arm I and Arm II (CAF therapy). The rate for Arm III (CAF therapy) was 61.5% (32/52), a little higher than that for the other two. As side effects due to the induction therapy, alopecia, fatigue, anorexia, nausea and vomiting, and leukopenia were observed in a relatively high proportion of patients. Mean values of CR duration, PR duration and the whole duration of remission in responding patients were 14.0 approximately 21.5 weeks, 24.0 approximately 32.2 weeks and 28.0 approximately 42.6 weeks, respectively, without any significant difference among the three groups given different maintenance therapies. The mean values of survival duration in responding patients were 27.1, 22.0 and 17.2 months, respectively for Arm I, Arm II and Arm III no significant difference being recognized in this point, either.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1988

[End result of preoperative adjuvant chemotherapy with oral 5-FU dry syrup in gastric cancer].

The purposes of this administration were to inactivate cancer cells liberated from the primary tumor, to prevent them from metastasizing to other organs and to treat established metastatic cancer. Sixty-one patients with advanced gastric cancer who had received preoperative 5-FU dry syrup administration and who had also undergone curative resection between 1976 and 1982, in addition to postoperative chemotherapy (more than 20 mg MMC, 5,000 mg 5-FU), (Group A) were admitted to the present study. Their survival rate was compared with that of 67 patients given curative resection for advanced cancer without preoperative 5-FU dry syrup, who received the same postoperative chemotherapy only (Group B) during the same period. The 5-year survival rate for Group A was 0.55 +/- 0.06, higher than the rate of 0.42 +/- 0.06 for Group B. Comparing the 5-year survival rates of both groups in terms of clinicopathological factors such as stage of cancer progression, serosal invasion, lymph node metastasis, and lymphangitic and blood vessel invasion, the 5-year survival rates for Group A were higher than those for Group B. There were significant differences for histological stage III and blood vessel invasion between the two groups. From these results, it is suggested that preoperative oral 5-FU dry syrup might be effective as an adjuvant therapy to surgery for gastric cancer.

Administration, Oral↗
PubMed1988

[Breast cancer surgery from the viewpoint of quality of life].

Recently, cancer therapy has been evaluated not only for the therapeutic results themselves but also in the quality of life of the treated patients. The first category of such efforts in breast cancer surgery is the introduction of conservative surgery, that is, muscle preserving operation, partial mastectomy, subcutaneous mastectomy and so on. The second approach is breast reconstruction after mastectomy, which has been improved with the progress in plastic surgery. Recent problems in the above respects in Japan are discussed.

Adult↗
PubMed1987

[Effects of estrogen and endocrine therapeutic agents on the estrogen receptor, progesterone receptor and DNA synthesis in MCF-7 human breast cancer cells using the whole cell uptake method].

In order to investigate the mechanisms of the endocrine therapeutic agents and the applicability of combined endocrine therapies for breast cancers, we studied the effects of estrogen and the endocrine therapeutic agents on estrogen receptor (ER), progesterone receptor (PgR), and DNA synthesis in MCF-7 human breast cancer cells, which is known to be sensitive to estrogen. ER and PgR of MCF-7 cells were determined by whole cell uptake method. In brief, intact MCF-7 cells cultured in the multi-well plates were incubated with various concentrations of tritiated estradiol (E2) or promegestone (R5020) at 37 degrees C for 1 hour. The characteristics of the hormone binding were analyzed by Scatchard plots. MCF-7 cells had single class of ER (Kd: 2.1 +/- 0.2 X 10(-10) M, MBC: 9.0 +/- 1.5 X 10(3) sites/cell) and PgR (Kd: 7.2 +/- 1.1 X 10(-10) M, MBC: 3.1 +/- 0.5 X 10(4) sites/cell). When cultured in the presence of 10(-8) M or 10(-6) M of E2, tamoxifen (TAM), R5020 or medroxyprogesterone acetate (MPA) for 48 hrs, the numbers of binding sites of ER and PgR altered, but the affinities of either of them did not change. E2(10(-8) or 10(-6) M) increased about twice the number of PgR. Although treatment of 10(-8) M TAM, a non-steroidal antiestrogen, slightly increased the number of PgR, 10(-6) M TAM significantly decreased the number of PgR. Both of R5020 (10(-8) or 10(-6) M) and MPA (10(-8) or 10(-6) M), synthetic progestins, decreased the number of ER dose-dependently. On the other hand, E2 (10(-8) and 10(-6) M) and R5020 (10(-8) M) enhanced DNA synthesis, but 10(-6) M TAM or MPA inhibited DNA synthesis. The effects of single, sequential and coincidental treatment of these agents were compared. The sequential treatment of 10(-8) M E2 for 36 hrs and followed 10(-6) M MPA for 36 hrs ("10(-8) M E2----10(-6) M MPA") and "10(-6) M TAM----10(-6) M MPA" inhibited DNA synthesis of MCF-7 cells more efficiently than 10(-6) M TAM alone or 10(-6) M MPA alone for 72 hrs. However, "10(-6) M MPA----10(-6) M TAM" inhibited DNA synthesis less than "10(-6) M TAM----10(-6) M MPA".(ABSTRACT TRUNCATED AT 400 WORDS)

Breast Neoplasms↗
PubMed1987

[Breast cancer and hormone therapy].

Recent changes in hormonal therapy for breast cancer were reviewed and discussed. In hormonal therapy for metastatic or recurrent cases, major forms of ablative therapy other than oophorectomy have been less popular because of the introduction of the hormone receptor assay, tamoxifen therapy, high-dose medroxyprogesterone acetate therapy, etc. Together with this, combined modality therapy including chemo-endocrine therapy or multi-hormone therapy has been investigated. Hormonal therapy as a post-surgical adjuvant therapy consists of oophorectomy (surgical or irradiation) and long-term administration of tamoxifen. Although these treatments are still associated with controversial results in several reports, further study and evaluation should be continued.

Breast Neoplasms↗
PubMed1987

[A case of small cell carcinoma of the esophagus].

A small cell carcinoma of the esophagus is a rare entity; only 101 cases have been reported in the world literature. In a 59-year-old man, complaining of dysphagia, a tumorous lesion was detected in the esophagus at the upper GI series. The histologic diagnosis of biopsy revealed an undifferentiated carcinoma or a malignant lymphoma. Preoperative radiotherapy was carried out, effectively decreasing the large tumorous lesion in size. Thereafter an esophagectomy and an esophagogastric anastomosis were done. The histologic diagnosis of the resected specimen revealed a small cell carcinoma of an intermediate cell type. The tumor cells failed to show cytoplasmic argyrophilia and an ultrastructural examination did not display any cells containing membrane-bound neurosecretory granules.

Carcinoma, Small Cell↗
PubMed1987

[Phase I study of a recombinant gamma interferon (S-6810)].

A phase I study of a recombinant gamma interferon (S-6810) was conducted in a cooperative study involving 11 institutions. S-6810 was administered at doses of 2, 4, 8, 12, 32 and 64 X 10(6) U/m2 by one-hour infusion for 5 consecutive days. A total of 40 courses were administered to 31 patients. High fever exceeding 38 degrees C with chills occurred in about 80% of patients. The incidences of other toxicities were fatigue in 50%, gastrointestinal toxicities in 30-40%, and changes in hepatic enzymes and hematologic toxicities in 20-30%. Dose-limiting factors were judged to be hypotension, leukopenia and central nervous toxicity. Maximum tolerated dose was 64 X 10(6) U/m2 and an optimal dose for phase II study was considered to be 6 X 10(6) U/m2 by daily chronic schedule. Blood concentration was highest at the end of infusion, and then decreased rapidly with a biphasic curve. The peak concentrations were elevated by escalation of doses. A partial response was observed in a patient with mycosis fungoides.

Adult↗
PubMed1987

[Studies on immunological parameters in patients with gastric carcinoma--with special reference to analyses with monoclonal antibodies of T-lymphocyte subsets and interleukin-2].

We have investigated the distributions of T-lymphocyte subsets and interleukin-2 in peripheral blood of 62 patients with gastric carcinoma. The antibody (OKT3, OKT4, OKT8, OKT4/8, Leu11, and Leu7) treated cells were analyzed on a Spectrum III automated flow cytometer. Interleukin-2 was measured by the tritium-labelled thymidine CTLL assay on the supernatants of peripheral blood lymphocytes of gastric cancer patients after 24 hours stimulation with phytohemagglutinin. The number of OKT3, OKT4 cells and the ratio of OKT4/8 were decreased in patients with advanced gastric carcinoma compared with early gastric carcinoma. The numbers of Leu11 and Leu7 cells in patients with stage II and III were in higher levels than those with stage IV. Interleukin-2 production was depressed in patients in advanced stage compared with those of early stage. We concluded that the T-lymphocyte subsets and the interleukin-2 production were useful immunological parameters for gastric cancer patients.

Adult↗
PubMed1986

[Serum thyroglobulin levels in patients with thyroid tumor].

Serum thyroglobulin (Tg) levels were measured in 15 normal volunteers, 69 patients with differentiated thyroid carcinoma, 22 with adenoma, 45 with adenomatous goiter, 5 with functioning adenoma and 24 with Graves' disease, utilizing a double antibody radioimmunoassay technique. Serum Tg levels in the normal volunteers were found to be less than 30 ng/ml as determined from their mean value, i.e., 16.9 +/- 13.4 ng/ml (mean + 2SD), whereas serum Tg in the patients with various thyroid disorders showed significantly elevated (P less than 0.01). Serum Tg of patients with differentiated thyroid carcinoma without distant metastasis was 71 +/- 7 ng/ml (mean +/- SE), that in adenoma 124 +/- 22 ng/ml, that in adenomatous goiter 147 +/- 19 ng/ml, that in functioning adenoma 120 +/- 41 ng/ml, and that in Basedow disease 122 +/- 22 ng/ml. Furthermore, it appears that Tg concentration in serum is correlated with the size of the nodules in differentiated thyroid carcinoma (P less than 0.01) and benign nodules (P less than 0.05). Present results suggest that thyroid tumor also release Tg into serum in addition to Tg stored in the normal tissue. Furthermore, the level of circulating Tg in patient is not correlated to the level of serum TSH. In treated differentiated thyroid carcinoma, serum Tg levels were markedly reduced (21 +/- 2 ng/ml) in patients with no evidence of either recurrences or metastases, but significantly elevated in those with recurrences and/or metastases (257 +/- 109 ng/ml). Therefore, serum Tg measurements in the follow-up of patients treated for differentiated thyroid carcinoma are useful in the search for recurrences or metastases.

Adenoma↗
PubMed1986

Right hepatic lobectomy for primary lymphoma: a case report and literature review.

Primary lymphoma of the liver is an extremely rare entity; only eight cases have been reported in the literature. We treated a 34-year-old man with primary hepatic lymphoma by right hepatic lobectomy, including right hemicolectomy the nephrectomy. The histological diagnosis was a small cell diffuse histiocytic lymphoma. Details of this case plus that of others in the literature are described in this report.

Adult↗
PubMed1986

[Significance of AFP in gastric cancer].

Serum alpha-fetoprotein (AFP) was positive in as few as 5.7-13.5% of gastric cancer patients prior to surgery, and most of the positive cases had cancer of stage IV or higher. Thus, the parameter did not seem to be very useful in diagnosis. It was positive in as many as 45% of terminal cancer patients, while many cases with AFP of more than 1000 ng/ml had metastases to the liver. Thus, AFP was proved to be useful for follow-up of the postoperative course. AFP staining was conducted in 29 dissected stomachs and five of them were positive for AFP staining.

Adult↗
PubMed1986

[Selection of therapeutic procedures according to the clinicopathological features of breast cancer].

The therapeutic guidelines for breast cancer do not depend on histological type, by which prognosis can differ according to minor variations. Treatment for breast cancer is subdivided into two categories; one is for primary breast cancer which is curable by surgery and the other is for advanced or recurrent breast cancer. In the former category, the surgical method and adjuvant therapy are selected according to stage. In the latter, endocrine therapy, chemotherapy, immunotherapy and radiotherapy are indicated in single or combined use. Main factors of selection in such cases are menopausal status, estrogen receptor status and site of distant metastasis.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

[Combined therapies with medroxyprogesterone acetate (MPA) in DMBA-induced rat mammary cancer].

Sixty-one female SD rats with 7, 12-dimethylbenz(a) anthracene (DMBA)-induced mammary cancer were divided into six groups according to the antitumor agent administered: MPA (20 mg/kg, Im), FT 207 (40 mg/kg, Ip), MPA (20 mg/kg, Im) + FT 207 (40 mg/kg, Ip), E2 priming (3 micrograms/body, Im, three days) + MPA (20 mg/kg, Im), E2 (3 mg/body, Im, three days) + MPA (20 mg/kg, Im) and control. The sizes of the tumors in all DMBA rats were measured at 1, 2, 3 and 4 weeks after the start of the administration, and the antitumor effects were compared among the groups. The antitumor effect of MPA + FT 207 was better than that when they were administered separately. It was shown that chemo-endocrine therapy with MPA was very effective. The antitumor effect was in the order of E2 priming + MPA, E2 + MPA and MPA among these three groups. E2 priming before MPA administration was thought to be very promising. The progesterone receptor (PgR) level tended to increase by E2 priming in DMBA tumors. Furthermore, in the E2 priming + MPA group, the tumors with high PgR levels before therapy tended to be more responsive than those with low PgR levels.

9,10-Dimethyl-1,2-benzanthracene↗